FORMULASI DAN EVALUASI NANOSTRUCTURED LIPID CARRIERS (NLC) SULFASALAZIN YANG BERPOTENSI UNTUK PENGGUNAAN RUTE TRANSDERMAL

• Main Author: Pinta Anugrah, Threefanny
• Format: Final Project
• Language: Indonesia
• Online Access: https://digilib.itb.ac.id/gdl/view/44290
• Institution: Institut Teknologi Bandung

Application of oral sulfasalazine provides a bioavailability less than 15% and side effect on mouth such as mouth ulcer and on the gastrointestinal tract such as nausea, diarrhea, dyspepsia, abdominal pain, and stomatitis. Transdermal dosage form is used to overcome this problem. Stratum corneum acts as barrier for penetration sulfasalazine pass through the skin. In a previous study SLN has been developed to improve sulfasalazine penetration through the stratum corneum, but the SLN provided bad physical stability. The NLC formula is developed to improved the physicochemical properties of SLN. NLC was prepared by combination of high speed homogenization with sonication method. NLC formulation optimum consist of lipid (8% w/v) with 90:10 apifil-oleic acid ratio, 8% of plantacare, and 1% of sulfasalazine. Characterization study was accomplished to particle size measurement, polydispersity index, potential zeta measurement, entrapment efficiency, physical stability and in vitro diffusion test. Particle size of obtained NLC was 284,3 nm with polydispersity index of 0,318 and potential zeta value of -33,11 mV. Entrapment efficiency sulfasalazine in NLC was 71,9%. Morphology by TEM revealed near spherical shape of NLC. NLC physical stability by freeze and thaw for 3 cycles and storage at 4 °C and 40 °C showed better stability of particle size than storage at 25 °C. In vitro diffusion test show that flux sulfasalazine with 124 × 10 -3 mg/cm 2 /hr was improved compared to SLN sulfasalazine. Flux sulfasalazine NLC loading gel was 10,1 × 10-3 mg/cm 2 /hr was preferable compared to sulfasalazine suspension with flux of 4,105 × 10 -3 mg/cm 2 /hr. NLC sulfasalazine provides better physicochemical properties in comparison of with SLN sulfasalazin.